Nuveen LLC Buys Shares of 193,591 Nautilus Biotechnology, Inc. $NAUT

Nuveen LLC bought a new stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 193,591 shares of the company’s stock, valued at approximately $167,000. Nuveen LLC owned about 0.15% of Nautilus Biotechnology as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Barclays PLC grew its position in shares of Nautilus Biotechnology by 17.9% in the fourth quarter. Barclays PLC now owns 125,204 shares of the company’s stock valued at $210,000 after purchasing an additional 19,030 shares during the last quarter. Jane Street Group LLC increased its holdings in Nautilus Biotechnology by 188.1% in the 4th quarter. Jane Street Group LLC now owns 108,545 shares of the company’s stock valued at $182,000 after buying an additional 70,863 shares during the period. XTX Topco Ltd bought a new stake in Nautilus Biotechnology in the 1st quarter valued at $31,000. Citadel Advisors LLC increased its holdings in Nautilus Biotechnology by 171.4% in the 4th quarter. Citadel Advisors LLC now owns 220,220 shares of the company’s stock valued at $370,000 after buying an additional 139,081 shares during the period. Finally, Millennium Management LLC bought a new stake in Nautilus Biotechnology in the 4th quarter valued at $63,000. 50.71% of the stock is owned by institutional investors and hedge funds.

Nautilus Biotechnology Price Performance

Shares of Nautilus Biotechnology stock opened at $0.66 on Friday. The company’s fifty day moving average price is $0.73 and its two-hundred day moving average price is $0.82. Nautilus Biotechnology, Inc. has a 52-week low of $0.62 and a 52-week high of $3.09. The firm has a market capitalization of $83.49 million, a PE ratio of -1.27 and a beta of 1.42.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its earnings results on Thursday, July 31st. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. Analysts predict that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current fiscal year.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.